We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.35%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$346M
AUM Growth
-$33M
Cap. Flow
-$24.2M
Cap. Flow %
-6.99%
Top 10 Hldgs %
58.05%
Holding
59
New
16
Increased
15
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$9.88M
2
ASND icon
Ascendis Pharma A/S
ASND
+$9.34M
3
FOLD
Amicus Therapeutics
FOLD
+$8.74M
4
MRSN
Mersana Therapeutics
MRSN
+$8.59M
5
VRNA
Verona Pharma
VRNA
+$5.57M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$20.4M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$12.8M
4
TGTX icon
TG Therapeutics
TGTX
+$9.2M
5
AXSM icon
Axsome Therapeutics
AXSM
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 77.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
$4.41M 1.27%
350,000
– –
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
$4.16M 1.2%
825,000
– –
RAPT
28
DELISTED
RAPT Therapeutics
RAPT
$3.7M 1.07%
+14,375
New +$3.19M
WVE icon
29
Wave Life Sciences
WVE
$1.12B
$3.61M 1.04%
425,000
-110,000
-21% -$1.21M
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.6B
$3.6M 1.04%
325,000
– –
NXTC icon
31
NextCure
NXTC
$24.4M
$3.52M 1.02%
+33,333
New +$4.1M
MYOV
32
DELISTED
Myovant Sciences Ltd.
MYOV
$3.51M 1.02%
250,000
-50,000
-17% -$930K
RETA
33
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.92M 0.84%
30,000
-20,000
-40% -$2.5M
ALT icon
34
Altimmune
ALT
$558M
$2.64M 0.76%
200,000
+50,000
+33% +$1,000K
RGNX icon
35
Regenxbio
RGNX
$534M
$2.06M 0.6%
+75,000
New +$2.45M
TPST icon
36
Tempest Therapeutics
TPST
$15.4M
$1.51M 0.44%
+4,744
New +$1.61M
QTTB icon
37
Q32 Bio
QTTB
$346M
$1.45M 0.42%
7,500
-5,556
-43% -$1.25M
IMV
38
DELISTED
IMV Inc. Common Shares
IMV
$1.44M 0.42%
+32,500
New +$1.46M
BIIB icon
39
Biogen
BIIB
$30.4B
$1.19M 0.34%
+4,200
New +$1.17M
CALC icon
40
CalciMedica
CALC
$11.6M
$953K 0.28%
+5,357
New +$1.12M
STSA
41
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$778K 0.22%
200,000
-140,000
-41% -$2.81M
MRNA icon
42
Moderna
MRNA
$24.5B
$708K 0.2%
10,000
– –
AKBA icon
43
Akebia Therapeutics
AKBA
$359M
$628K 0.18%
+250,000
New +$2.19M
AMRN
44
Amarin Corp
AMRN
$292M
$421K 0.12%
+5,000
New +$599K
BMY.RT
45
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$281K 0.08%
+125,000
New +$357K
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
$247K 0.07%
+4,500
New +$242K
ACAD icon
47
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-165,000
Closed -$8M
AXSM icon
48
Axsome Therapeutics
AXSM
$11.8B
– –
-100,000
Closed -$8.23M
FXE icon
49
Invesco CurrencyShares Euro Currency Trust
FXE
$354M
– –
-2,000
Closed -$212K
GILD icon
50
CALL
Gilead Sciences
GILD
$167B
– –
-125,000
Closed -$9.62M
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ghost Tree Capital held 59 positions worth $346M, down 8.7% from $379M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Ghost Tree Capital withdrew a net $24.2M in Q3 2020, closing 13 positions and reducing 9 holdings. Its most notable exit was Immunomedics Inc, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 71% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $9.13M.

  • Ghost Tree Capital's largest Q3 2020 buy was Sarepta Therapeutics: 65,000 shares worth $9.13M.
  • Ghost Tree Capital added most to Ascendis Pharma A/S in Q3 2020, an estimated $9.34M increase.
  • Ghost Tree Capital's biggest Q3 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $13M.
  • Ghost Tree Capital fully exited Immunomedics Inc in Q3 2020, selling an estimated $20.4M.
  • Ghost Tree Capital's ten largest holdings make up 58% of its $346M portfolio in Q3 2020.
  • Ghost Tree Capital opened 16 new positions and closed 13 in Q3 2020.
  • Ghost Tree Capital's portfolio value fell 8.7% quarter-over-quarter to $346M.

Based on Ghost Tree Capital's 13F filing for Q3 2020, filed 16 Nov 2020.